Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efavirenz
- Development stage
- Approved
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with other antiretroviral agents to treat human immunodeficiency virus type 1 (HIV-1) infection in adults and children. It works by noncompetitively inhibiting the HIV-1 reverse transcriptase enzyme, thereby blocking viral RNA-directed DNA polymerase activity and reducing the amount of HIV in the blood. Efavirenz does not cure HIV but helps lower the risk of developing acquired immunodeficiency syndrome (AIDS) and related illnesses. The drug was approved by the FDA on September 17, 1998[1][2][3][4][7][8].
- Brand names
- Sustiva
- Other names
- efavirenz
02
Targets
HTR6 (5-hydroxytryptamine receptor 6)CHRM3 (M3)Human immunodeficiency virus type 1 reverse transcriptaseHTR2A (Serotonin receptor 5-HT2A)M1 (Muscarinic acetylcholine receptor M1)HTR2C (5-hydroxytryptamine 2C receptor)HTR3A (5-hydroxytryptamine receptor 3A)
Beyond the preview
Go deeper on efavirenz.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efavirenz.